MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17192931.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
Medical subject headings
- Biomarkers, Tumor
- Brain Neoplasms
- DNA Methylation
- Dacarbazine
- Glioma
- Promoter Regions, Genetic
- Tumor Suppressor Protein p14ARF